Download - Bayer HealthCare

More documents

Recommendations

Info

Every tumor is unique. Biology lab assistant Kirsten SteinerHahn fi rst inspects tissue specimens with the naked eye. The tumor samples then undergo numerous further analyses. 16 research and development
€1,962 million of the Bayer Group’s total research and development (r&D) spending went to Bayer HealthCare in 2012, corresponding to 65.1 percent of the group’s entire research expenditure, or 10.5 percent of Bayer HealthCare’s sales. Some 7,500 employees research and develop innovative active ingredients for the treatment of diseases where there is a high level of medical need. Drug discovery in Bayer HealthCare’s Pharmaceuticals Division is concentrated on the areas of Cardiology, Oncology, Hematology and Women’s Healthcare, while the corresponding mechanisms of inflammation and the development of new therapeutic options in oph- thalmology are also of interest. The division aims to identify low-molecular-weight substances as well as to develop new biologics. It also evolves products that have already been granted regulatory approval, for example by developing novel formulations. In many of these projects, Bayer’s scientists work together in close collaboration with external cooperation partners. rESEArCH AnD DEvEloPMEnT One example of an innovative active ingredient is the anticoagulant Xarelto (rivaroxaban) which was invented in Bayer’s laboratories in Wuppertal and co-developed with Janssen Pharmaceuticals. The extensive clinical trial program conducted for rivaroxaban which will have involved more than 100,000 patients once all studies are completed makes it the most studied oral, direct Factor Xa inhibitor in the world today. The clinical development program investigated the inhibitor’s potential in the prevention and treatment of a broad spectrum of acute and chronic thromboembolic disorders, including stroke prevention in patients with atrial fibrillation, treatment of deep vein thrombosis and pulmonary embolism, prevention of recurrent deep vein thrombosis or pulmonary embolism, and finally secondary prevention of acute coronary syndrome. Another innovative substance from Bayer’s research laboratories is riociguat, the first drug from a new class of vasodilatative substances. This oral product is being developed for the treatment of various forms of pulmonary hypertension, a rare but lifethreatening disease. Further priorities in cardiology research are heart failure and kidney disorders. The functions of the heart and kidneys are mutually interdependent and heart and kidney diseases often share common underlying disease mechanisms. Despite major progress in the fight against cancer, there is still a high medical need for therapies to prolong life and improve the quality of life. The development pipeline in Oncology comprises various targeted antibodies, antibody-drug conjugates as well as low-molecular-weight substances. These include, in addition to Nexavar (sorafenib), a co-development with Onyx Pharmaceuticals, the substance regorafenib, which inhibits various enzymes involved in tumor growth and the formation of new blood vessels (neoangiogenesis), and radium-223 dichloride, a novel alpha-pharmaceutical drug which is being co-developed with the norwegian company Algeta ASA for the treatment of tumor types which have already formed metastases in the bones. Radium-223 dichloride emits targeted alpha radiation to eliminate cancer cells in the bones. It was filed for regulatory approval for the treatment of castration-resistant prostate 17
Page 1 and 2: Bayer HealthCare A Company Overview
Page 3 and 4: innovations in health care Bayer He
Page 5 and 6: or farm animals for food production
Page 7 and 8: The goals of the Animal Health Divi
Page 9 and 10: A growing number of individuals wor
Page 11 and 12: Bayer HealthCare’s Medical Care D
Page 13 and 14: Bayer HealthCare’s success story
Page 15: Continued from page 13 of the uteru
Page 19 and 20: expertise. The current R&D focus in
Page 21 and 22: Bayer HealthCare manufactures produ
Page 23 and 24: As an innovation- and growth-orient
Page 25 and 26: in the 21st century, the world will
Page 27 and 28: Bayer HealthCare names - Figures -
Page 29 and 30: Germany United States China Japan M

Download - Bayer HealthCare

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?